Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression (Q43288450)

18 November 2017

Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression (English)

1 reference

single-nucleotide polymorphism

18 November 2017

1 reference

Pei-Chieng Cha

1

1 reference

18 November 2017

Taisei Mushiroda

2

1 reference

18 November 2017

Hitoshi Zembutsu

3

1 reference

18 November 2017

Hiromasa Harada

4

1 reference

18 November 2017

Noriyuki Shinoda

5

1 reference

18 November 2017

Shunji Kawamoto

6

1 reference

18 November 2017

Rai Shimoyama

7

1 reference

18 November 2017

Toshihiko Nishidate

8

1 reference

18 November 2017

Tomohisa Furuhata

9

1 reference

18 November 2017

Kazuaki Sasaki

10

1 reference

18 November 2017

Koichi Hirata

11

1 reference

18 November 2017

Yusuke Nakamura

12

1 reference

18 November 2017

21 August 2009

1 reference

Journal of Human Genetics

18 November 2017

1 reference

18 November 2017

54

1 reference

18 November 2017

10

1 reference

18 November 2017

572-580

1 reference

https://scigraph.springernature.com/pub.10.1038/jhg.2009.80

18 November 2017

0 references

cites work

Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Role of pharmacogenetics in irinotecan therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Clinical pharmacokinetics of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Irinotecan: a new antineoplastic agent for the management of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Phase II study of activated charcoal to prevent irinotecan-induced diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Pharmacogenetic pathway analysis of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Pharmacogenetics of irinotecan metabolism and transport: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Insights, challenges, and future directions in irinogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

A high-throughput SNP typing system for genome-wide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Haploview: analysis and visualization of LD and haplotype maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Pharmacology of irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

Irinotecan in the treatment of colorectal cancer: clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

7 January 2021

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

7 January 2021

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

7 January 2021

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

7 January 2021

Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

7 January 2021

Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

7 January 2021

Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

7 January 2021

Haplotype structures of the UGT1A gene complex in a Japanese population

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2009.80

7 January 2021

Identifiers

DOI

10.1038/JHG.2009.80

1 reference

18 November 2017

1 reference